Total psoriasis regression in a patient with chronic myeloid leukemia treated using nilotinib
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu kazuistiky, časopisecké články
PubMed
40016401
PubMed Central
PMC12031779
DOI
10.1007/s00277-025-06228-x
PII: 10.1007/s00277-025-06228-x
Knihovny.cz E-zdroje
- Klíčová slova
- Adverse effects, Chronic myeloid leukemia, Nilotinib, Psoriasis, Tyrosine kinase inhibitors,
- MeSH
- chronická myeloidní leukemie * farmakoterapie komplikace MeSH
- inhibitory proteinkinas * terapeutické užití škodlivé účinky aplikace a dávkování MeSH
- lidé MeSH
- psoriáza * farmakoterapie komplikace chemicky indukované patologie MeSH
- pyrimidiny * terapeutické užití škodlivé účinky aplikace a dávkování MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
- Názvy látek
- inhibitory proteinkinas * MeSH
- nilotinib MeSH Prohlížeč
- pyrimidiny * MeSH
Chronic myeloid leukemia (CML) treatment has been revolutionized over last 20 years because of tyrosine kinase inhibitors (TKIs) and patients with CML now have life expectancy of general population. Chronic TKI treatment may cause adverse effects (AEs) that vary in frequency and severity. Nilotinib shows common AEs with metabolic changes and skin AEs. Here, we present a case report of patient who experienced full psoriasis regression while treated with nilotinib. Dose reductions and an attempt to stop nilotinib treatment resulted in prompt psoriasis reappearance. This is the first documented case of positive effect of nilotinib on psoriasis.
Zobrazit více v PubMed
Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016. 128(1):17–23. PubMed
Berger MG, Pereira B, Rousselot P et al. Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome. Br J Haematol. 2019. 187(3):337–346. PubMed
Caldemeyer L, Dugan M, Edwards J, Akard L. Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Curr Hematol Malig Rep. 2016. 11(2):71 − 9. PubMed
Steegmann JL, Cervantes F, le Coutre P et al. Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leuk Lymphoma. 2012. 53(12):2351-61. PubMed
Jabbour E, Sasaki K, Haddad FG et al. Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am. J. Hematol. 2022. 97(11):1413–1814. PubMed PMC
Nagai T, Karakawa M, Komine M et al. Development of psoriasis in a patient with chronic myelogenous leukaemia during nilotinib treatment. Eur J Haematol. 2013. 91(3):270–272. PubMed
Day E, Waters B, Speigel K et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol. 2008. 599(1–3):44–53. PubMed
